Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 653 - 676
Published: May 15, 2024
Language: Английский
Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)
Published: April 2, 2025
Abstract Phototherapy has emerged as a promising modality in cancer treatment, garnering considerable attention for its minimal side effects, exceptional spatial selectivity, and optimal preservation of normal tissue function. This innovative approach primarily encompasses three distinct paradigms: Photodynamic Therapy (PDT), Photothermal (PTT), Photoimmunotherapy (PIT). Each these modalities exerts antitumor effects through unique mechanisms—specifically, the generation reactive oxygen species (ROS), heat, immune responses, respectively. However, significant challenges impede advancement clinical application phototherapy. These include inadequate ROS production rates, subpar photothermal conversion efficiency, difficulties tumor targeting, unfavorable physicochemical properties inherent to traditional phototherapeutic agents (PTs). Additionally, hypoxic microenvironment typical tumors complicates therapeutic efficacy due limited agent penetration deep-seated lesions. To address limitations, ongoing research is fervently exploring solutions. The advantages offered by nano-PTs nanocarrier systems aim enhance approaches’ effectiveness. Strategies such generating situ within or inhibiting mitochondrial respiration while targeting HIF-1α pathway may alleviate hypoxia. Moreover, utilizing self-luminescent materials, near-infrared excitation sources, non-photoactivated sensitizers, wireless light delivery can improve penetration. Furthermore, integrating immunoadjuvants modulating immunosuppressive cell populations deploying checkpoint inhibitors holds promise enhancing immunogenic death PIT. review seeks elucidate fundamental principles biological implications phototherapy discussing dominant mechanisms advanced strategies designed overcome existing challenges—ultimately illuminating pathways future aimed at amplifying this intervention’s efficacy.
Language: Английский
Citations
0
ACS Nano, Journal Year: 2025, Volume and Issue: unknown
Published: April 14, 2025
In immunotherapy for malignant tumors, the dysregulation of balance between effector T cells and regulatory (Tregs) uncertain efficacy due to individual differences have been considered as two critical challenges. this study, we engineered an injectable nanocomposite hydrogel system (SNAs@M-Gel) capable suppressing Treg proliferation blocking PD-1/PD-L1-mediated immune evasion effectively, achieved through stimulus-responsive modulation multiple tumor-associated microRNAs. Simultaneously, enables microRNA-dependent photothermal immunotherapy, facilitating a highly efficient personalized approach tumor treatment. Specifically, oxidized sodium alginate (OSA) cancer cell membrane (CCM)-encapsulated spherical nucleic acid nanoparticles (SNAs@M) were used construct SNAs@M-Gel in situ at site formation pH-sensitive Schiff base bonding cross-linking using endogenous calcium ions (Ca2+). During treatment, was retained locally up 10 days, SNAs@M continuously released into microenvironment. Through targeting ability CCM, precisely entered specifically hybridized with overexpressed miR-214 miR-130a, leading significant downregulation PD-L1 expression on restoration cytotoxic lymphocyte (CTL) function suppressed by Tregs, thereby remodeling addition, miRNAs functioned agents, aggregation SNAs allowing localized production agents directly inside cells, which, under near-infrared (NIR) irradiation, promoted selective therapy. This cascade events not only led destruction primary but also resulted release substantial number tumor-related antigens, which triggered maturation adjacent dendritic (DCs) subsequent priming tumor-specific CTLs, while simultaneously depleting reversing tumor-promoting microenvironment enhancing overall therapeutic immunotherapy.
Language: Английский
Citations
0
Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown
Published: April 15, 2025
Abstract Pyroptosis, a programmed necrotic cell death mediated by gasdermin, can activate strong immune responses and serve as potential target for cancer therapy. Nevertheless, the relatively large molecular size negative surface charge of gasdermin impede them from effectively intracellular delivery directly inducing pyroptosis. Here, cytosolic protein system, fluorinated iron oxide nanoparticles (FIONPs) is reported, which self‐assemble with active A3 (GSDMA3) via noncovalent interactions trigger pyroptosis in 4T1 cells. It proved that system versatile various cargo proteins (ribonuclease A, saporin, β‐galactosidase, bovine serum albumin) different isoelectric points weights, without compromising their biological activity vitro. What's more, under magnetic drive, FIONPs facilitate transport GSDMA3 vivo, further augmenting tumor suppression response. Overall, magnetic‐driven provide an effective transductions, application reveals direct significantly elicits robust antitumor immunity induction
Language: Английский
Citations
0
ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown
Published: April 16, 2025
STING activation is a promising application therapeutic strategy for cancer immunotherapy. In particular, MSA-2 as an oral agonist discovered to have antitumor activity. However, how improve the effect of very valuable contribution Here, we use two strategies amplify by phospholipid nanoparticles delivering mRNA and copper-modified MSA-2. We synthesized new series ionizable optimized nanoparticle (1AP24) mRNA, increasing expression protein bind more Second, (MSA-2-Cu), which induced cell death Cu2+ toxicity. Combining 1AP24@STING MSA-2-Cu can crucially decrease tumor growth increase mouse's survival. It treatment through amplifying pathway.
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 653 - 676
Published: May 15, 2024
Language: Английский
Citations
3